US 5324731A
· Kaddurah-Daouk et al.
· 1994
[cited by applicant]
US 5676978A
· Teicher et al.
· 1997
[cited by applicant]
US 6316503B1
· Li et al.
· 2001
[cited by applicant]
US 7247748B2
· Thompson et al.
· 2007
[cited by applicant]
US 7365085B2
· Bhat et al.
· 2008
[cited by applicant]
US 7560586B2
· Thompson et al.
· 2009
[cited by applicant]
US 7576215B2
· Collini et al.
· 2009
[cited by applicant]
US 7799782B2
· Munson et al.
· 2010
[cited by applicant]
US 7998995B2
· Boren et al.
· 2011
[cited by applicant]
US 9399028B2
· Tavazoie
· 2016
[cited by examiner]
US 9526710B2
· Tavazoie
· 2016
[cited by examiner]
US 9707195B2
· Tavazoie
· 2017
[cited by examiner]
US 9962348B2
· Tavazoie
· 2018
[cited by examiner]
US 20040072868A1
· Collins et al.
· 2004
[cited by applicant]
US 20050282908A1
· Collins et al.
· 2005
[cited by applicant]
US 20100048944A1
· Parhami
· 2010
[cited by applicant]
US 20110166079A1
· Vitek et al.
· 2011
[cited by applicant]
US 20120156216A1
· Oh
· 2012
[cited by applicant]
US 20130071403A1
· Rolland et al.
· 2013
[cited by applicant]
JP H11507371A
· 1999
[cited by applicant]
JP 2008509948A
· 2008
[cited by applicant]
JP 2011525616A
· 2011
[cited by applicant]
JP 2012503984A
· 2012
[cited by applicant]
JP 2012528180A
· 2012
[cited by applicant]
WO 03082802A1
· 2003
[cited by applicant]
WO 2004043939A1
· 2004
[cited by applicant]
WO 2006004030A1
· 2006
[cited by applicant]
WO 2006018182A1
· 2006
[cited by applicant]
WO 2007002563A1
· 2007
[cited by applicant]
WO 2008011071A2
· 2008
[cited by applicant]
WO 2010036959A2
· 2010
[cited by applicant]
WO 2010138598A2
· 2010
[cited by applicant]
WO 2011115892A1
· 2011
[cited by applicant]
WO 2011130426A2
· 2011
[cited by applicant]
WO 2011158667A1
· 2011
[cited by applicant]
WO 2012095505A1
· 2012
[cited by applicant]
WO 2012096573A1
· 2012
[cited by applicant]
WO 2012135082A1
· 2012
[cited by applicant]
Bergenfelz et al., “Systemic Monocytic-MDSCs are Generated from Monocytes and Correlate with Disease Progression in Breast Cancer Patients,” PLoS One (2015); 10(5):e0127028 (pp. 1-15).
[cited by applicant]
Chuu et al., “Modulation of Liver X Receptor Signaling as Novel Therapy for Prostate Cancer,” Journal of Biomedical Science (Mar. 20, 2007): 14:543-553.
[cited by applicant]
Gielen et al., “Increase in Both CD14-Positive and CD15-Positive Myeloid-Derived Suppressor Cell Subpopulations in the Blood of Patients with Glioma But Predominance of CD15-Positive Myeloid-Derived Suppressor Cells in …
[cited by applicant]
Gros et al., “Myeloid Cells Obtained form the Blood but not from the Tumor Can Suppress T-cell Proliferation in Patients with Melanoma,” Clin Cancer Res. (Oct. 1, 2012); 18(19):5212-5223.
[cited by applicant]
Haas, M.J., “Melanoma: three ways around BRAF inhibition,” SciBX 3(47); doi: 10.1038/scibx.2010.1400 published online Dec. 9, 2010.
[cited by applicant]
Li et al., “miR-495 and miR-551a inhibit the migration and invasion of human gastric cancer cells by directly interacting with PRL-3,” Cancer Lett (Mar. 30, 2012); 323(1):41-47.
[cited by applicant]
Obermajer et al., “PGE2-Induced CXCL12 Production and CXCR4 Expression Controls the Accumulation of Human MDSCs in Ovarian Cancer Environment,” Cancer Res. (2011); 71(24):7463-7470.
[cited by applicant]
Pencheva et al., “Broad-Spectrum Therapeutic Suppression of Metastatic melanoma thorugh Nuclear Hormone Receptor Activation,” Cell (Feb. 27, 2014); 156(5):986-1001.
[cited by applicant]
Pencheva et al., “Control of metastatic progression by microRNA regulatory networks,” Nature Cell Biology (Jun. 3, 2013); 15(6):546-554.
[cited by applicant]
Rudolph et al., “Increased frequencies of CD11b+CD33+CD14+HLA-DRlow myeloid-derived suppressor cells are an early eent in melanoma patients,” Experimental Dermatology (2014); 23:199-218.
[cited by applicant]
Scoles et al., “LiverX receptor agonist inhibits proliferation of ovarian carcinoma cells stimulated by oxidized low density lipoprotein,” Gynecology Oncology (2010): 116:109-116.
[cited by applicant]
Talmadge et al., “History of myeloid derived suppressor cells (MDSCs) in the macro-and micro-environment of tumour-bearing hosts,” Nat Rev Cancer (2013); 13(10):739-752.
[cited by applicant]
Weber et al., “Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab,” Cancer Immunol Res (Apr. 2016); 4(4):345-353.
[cited by applicant]
Zhang et al., “Liver X receptor activation induces apoptosis of melanoma cell through caspase pathway,” Cancer Cell International (Feb. 25, 2014); 14(1):16 (1-6).
[cited by applicant]
Zhang et al., A novel subset of B7—H3+CD14+HLA-DR-/low myeloid-derived suppressor cells are associated with progression of human NSCLC, Oncolmmunology (Feb. 2015): 4(2): e977164-1-e977164-12.
[cited by applicant]
Zigler et al., “Tumor Immunotherapy in Melanoma—Strategies for Overcoming Mechanisms of Resistance and Escape,” Am J Clin Dermatol (2008); 9(50):307-311.
[cited by applicant]
Marino Jr., J. P. “The Discovery of Tertiary-Amine LXR Agonists with Potent Cholesteroal Efflux Activity in in Macrophages”, Bioorganic & Medicinal Chemistry Letters (2009), vol. 19, pp. 5617-5621.
[cited by applicant]
Rough, J. J.et al., “Anti-Proliferative Effect of LXR Agonist T0901317 in Ovarian Carcinoma Cells”, J. of Ovarian Research (2010), vol. 3:13, 10 pgs.
[cited by applicant]
Extended European Search Report issued Jun. 28, 2023 in related European Patent Application No. 23155232.4, 10 pgs.
[cited by applicant]